3 results match your criteria: "and Hospital Santa Maria della Misericordia[Affiliation]"
The discovery of mutations in acute myeloid leukemia.
Haematologica
September 2024
Institute of Hematology and CREO, University and Hospital Santa Maria della Misericordia of Perugia, Perugia.
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Blood
April 2022
Section of Hematology and Center for Hemato-Oncological Research (CREO), Department of Medicine and Surgery, University of Perugia and Hospital Santa Maria della Misericordia, Perugia, Italy.
Hairy cell leukemia (HCL) responds very well to frontline chemotherapy with purine analogs (cladribine and pentostatine). However, approximately half of patients experience 1 or more relapses, which become progressively resistant to these myelotoxic and immunosuppressive agents. At progression, standard therapeutic options include a second course of purine analogs alone or in combination with rituximab and, upon second relapse, therapy with the anti-CD22 immunotoxin moxetumomab pasudotox.
View Article and Find Full Text PDFCardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.
Eur J Intern Med
August 2011
Unit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Clinical and Experimental Medicine, University of Perugia, and Hospital Santa Maria della Misericordia, Piazzale Menghini, Perugia, Italy.
Background: Many adults are not at recommended lipid levels and the extent of treatment of dyslipidemia remains poor. We investigated the burden of cardiovascular risk and the distance of lipid fractions from the recommended targets by statin therapy and risk status in patients referred to a tertiary care lipid clinic.
Methods: Assessment of cardiovascular risk factors was performed in 1657 patients, mostly dyslipidemics, referred by family physicians to our Lipid Clinic, 393 patients being under statin therapy.